不同 rhBMP-2 剂量的双相磷酸钙在大鼠中的成骨活性。
Osteoinductive activity of biphasic calcium phosphate with different rhBMP-2 doses in rats.
机构信息
Resident, Department of Periodontology, Research Institute for Periodontal Regeneration, College of Dentistry, Yonsei University, Seoul, Korea.
出版信息
Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Apr;113(4):480-7. doi: 10.1016/j.tripleo.2011.04.013. Epub 2011 Jul 20.
OBJECTIVE
The aim of the current study was to determine whether a hydroxyapatite (HA)/beta-tricalcium phosphate (β-TCP) ratio of 20/80 impregnated with recombinant human bone morphogenetic protein (rhBMP-2) enhances new bone formation and to evaluate the dose-dependent response of rhBMP-2.
STUDY DESIGN
Critical-sized calvarial defects were made in rats, and biphasic calcium phosphate (BCP) with different rhBMP-2 doses was loaded into rat calvarial defects. The animals were allowed to heal for either 2 or 8 weeks.
RESULTS
The percentages of new bone after 2 and 8 weeks of healing were significantly greater in the rhBMP-2-treated groups (at all doses) than in the control groups. The percentage of remaining BCP was significantly lower at 8 weeks than at 2 weeks in all groups that included BCP.
CONCLUSIONS
rhBMP-2 administered using a BCP carrier significantly induces new bone formation. A dose-dependent response was not shown in the present study.
目的
本研究旨在确定羟磷灰石（HA）/β-磷酸三钙（β-TCP）比例为 20/80 并负载重组人骨形态发生蛋白（rhBMP-2）是否能增强新骨形成，并评估 rhBMP-2 的剂量依赖性反应。
研究设计
在大鼠颅骨缺损处制备临界尺寸的骨缺损，并将不同 rhBMP-2 剂量的双相磷酸钙（BCP）加载到大鼠颅骨缺损处。让动物分别愈合 2 或 8 周。
结果
在治疗组（所有剂量）中，愈合 2 周和 8 周后的新骨百分比明显高于对照组。在所有包含 BCP 的组中，8 周时的剩余 BCP 百分比明显低于 2 周时。
结论
使用 BCP 载体给予 rhBMP-2 可显著诱导新骨形成。本研究未显示出剂量依赖性反应。
Zotero 插件